NHS England South West

Subject: Specialised Services Circular (SSC)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2792	**NHS England Clinical Commissioning Policy: NHS England Clinical Commissioning Policy: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older) [2319]**	Paediatric patients: University Hospitals Bristol and Weston Adult patients: University Hospitals Bristol and Weston North Bristol Trust Royal United Hospitals Bath

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? No

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

NHS England South West

All Chief Executives

All Medical Directors

All Chief Pharmacists

Specialised Commissioning South West
NHS England
100 Temple Street
Bristol
BS1 6AG
Email: england.speccomm-southwest@nhs.net

7 March 2025

Dear Colleagues,

Re: NHS England Clinical Commissioning Policy: NHS England Clinical Commissioning Policy: Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older) [2319]

I am writing to advise you regarding the funding position on the recently published NHS England Clinical Commissioning Policy (CCP) for the use of etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older).

The CCP can be found at https://www.england.nhs.uk/publication/etanercept-and-adalimumab-for-the-treatment-of-deficiency-of-adenosine-deaminase/. Etanercept and adalimumab will be routinely commissioned from 26th February 2025 in line with the CCP.

In addition, NHS England will commission etanercept and adalimumab in children aged 2-4 years where etanercept and adalimumab is used in accordance with the NHS England policy 'Commissioning medicines for children in specialised services' for younger patients in accordance with the etanercept and adalimumab dosage as described in the BNF for Children [Adalimumab | Drugs | BNFC | NICE; Etanercept | Drugs | BNFC | NICE]. In this setting etanercept and adalimumab should only be requested by and administered in specialised treatment centres and the use of the etanercept and adalimumab should be discussed at a multi-disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area. Separate Blueteq registration forms for registration of adults and children have been made available. It should also be noted that etanercept and adalimumab should be used within the Trusts governance framework as etanercept and adalimumab are not licensed for use in children.

In addition:

- Trusts must ensure that only invoices for the drug procurement costs of etanercept and adalimumab in this indication are invoiced to NHSE and that they are also submitting complete and accurate information via the high-cost drugs minimum dataset (MDS). All other on costs are in block arrangements.

- In line with the terms and conditions included in the NHS Standard Contract and as per the agreement that Cancer Services are commissioned with Trusts, Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust invoices will be contingent on the completion of the MDS record and this information being made available in a timely way.
- Patients must be registered via Blueteq and meet the clinical criteria on the registration form. This letter gives the required one month's notice as per Schedule 2 Part G (Other Local Agreements, Policies and Procedures) of your Specialised Services contract for prior approval for this treatment/indication. From one month of the date specified above, NHS England will only reimburse these treatments for patients that have been confirmed as meeting the eligibility criteria via the formal Prior Approval Scheme (i.e. Blueteq). You may wish to use the prior approval mechanism earlier than this to expedite access to these drugs.
- **Payment of Trust invoices will be contingent on Blueteq registration and MDS record applicable to the drug being completed and this information being made available in a timely way. Please note there are different Blueteq registration forms for those aged 5 years and over/adults and for children aged 2 – 5 years.**
- Trusts must ensure that local governance aspects (e.g. technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate) in order to permit the safe delivery of this therapy.

Trusts should refer to the CAP portal for further information on the PAS price. The CAP portal is available at https://nhsengland.sharefile.eu/Authentication/Login

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

With best wishes,



Emma Redfern
Medical Director NHS England South West Region

Tracey Williams
Principal Pharmacist